CTRI/2023/09/057619进行中（未招募）Unknown
An open label, multicenter, balanced, randomized, parallel, three-treatment, three arm, single-period, single dose comparative bioavailability study of Leuprolide acetate for depot suspension 30 mg for 4-month administration of Pharmathen S.A., Greece, with LUPRON DEPOT (Leuprolide Acetate for Depot Suspension) 30 mg for 4-month administration of AbbVie Inc. North Chicago, IL 60064 in adult male subjects with prostatic cancer undergoing initial therapy of leuprolide acetate 30 mg under fasting conditions. - 22-VIN-0466
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male patients between age group of 18 and 75 years (both inclusive) and having a BMI of 18.5-30 kg/m2 (both inclusive).
- •2.Ability to understand and provide written informed consent prior to participation in the study and willing to comply with the study requirements as per protocol.
- •3.Patients who require Leuprolide Acetate Depot Injection, 30 mg every 16 weeks.
- •4.Patients with histologically/cytologically confirmed advanced carcinoma of prostate (Stage T(1b-4), N(any) , M(any)) who would be benefit from GnRH agonist .
- •5.Newly diagnosed advanced prostatic cancer patients that are undergoing initial therapy of leuprolide acetate 30 mg.
- •6.Testosterone levels = 1.5ng/mL at screening.
- •7.Patients with an ECOG Performance Status Score < 2.
- •8.Patients with hemoglobin = 9.0 g/dL .
- •9.No history of addiction to any recreational drug or drug dependence or alcohol addiction.
- •10.Non-smoker or ex-smoker who has not used any nicotine containing products in the last 6 months before day 1 of study treatment.
- •11.Patients with HbA1c = 7 % at screening.
- •12.Patients with life expectancy of at least 6 months at the time of enrolment as judged by Investigator.
- •13.Patients/ partner agreeing to use adequate contraceptive methods during the study.
排除标准
- •1.Known hypersensitivity or contraindication to GnRH, GnRH agonist or to any of the components of investigational product.
- •2.History of prostatic surgery (e.g., radical prostatectomy, transurethral resection of the prostate [TUR-P]) ,orchiectomy, adrenalectomy and hypophysectomy.
- •3.History of radiotherapy, chemotherapy, immunotherapy, radiation therapy, cryotherapy, strontium, or biological response modifiers as prostate therapy within 8 weeks prior the screening visit .
- •4.Patients that received hormonal manipulation within 32 weeks prior the screening visit (i.e. GnRH analogues, estrogen, megace and phytotherapy).
- •5.Patients requiring additional treatment (i.e. radiotherapy).
- •6.History of hypogonadism.
- •7.Received therapy with finasteride or ketoconazole within 1 week prior to the Screening Visit; dutasteride within 25 weeks prior to the Screening Visit.
- •8.Received therapy with a GnRH analog (1-year implant) within 60 weeks prior to the Screening Visit.
- •9.Positive tests for drug or alcohol abuse at screening or check in.
- •10.Patient had major surgery (other than those specified in criteria 2) within 4 weeks prior to study entry, or who have not recovered from prior major surgery.
- •11.Participants with inadequate mass in the gluteal to receive the intramuscular drug injection.
- •12.Patients with known positivity for human immunodeficiency virus (HIV), HBsAg or HCV.
- •13.History of difficulty with donating blood or difficulty in accessibility of veins.
- •14.Donation of blood (1 unit or 350 ml) within 90 days prior to receiving the first dose of investigational medicinal product for the current study.
- •15.Clinical indication of urinary tract obstruction.
- •16.History or presence of any uncontrolled debilitating systemic disease (e.g. cardiovascular disease, hypertension, diabetes mellitus etc.).
- •17.Significant pre-existing cardiovascular co morbidities i.e. Myocardial infarction within 6 month prior to screening, Unstable angina, Congestive cardiac failure, Cardiac arrhythmia, History of familial long QT syndrome.
- •18.Known CNS metastasis.
- •19.Patients having history of convulsion, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs.
- •20.Concurrent medications that may prolong the QT/QTc interval.
- •21.A marked baseline prolongation of QTc interval (QTc interval >450 milliseconds (ms) QTc interval to be calculated with Bazett’s Formula).
- •22.History of other malignancies in the last 5 years (except in situ cancer of cervix or basal or squamous cell skin cancer).
- •23.Participation in any clinical study within 90 days prior to receiving the first dose of Investigational Product.
- •24.Any condition/ abnormal baseline findings that in the investigators’ judgment might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to obtain the objective of the study e.g. low expectation of compliance to dosing or expected changes in concomitant medication that may interfere in study.
研究者
相似试验
进行中（未招募）
不适用
A study of Capecitabine 200 mg/ ml with Xeloda 500 mg (Capecitabine) at a dose of 2000 mg in adult human cancer patients under fed conditions.CTRI/2020/10/028417Shilpa Medicare Limited
已完成
不适用
Imatinib Mesylate Oral Solution 400mg/5ml with Gleevec® (Imatinib mesylate) Tablets 400mg in adult human subjects with Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumors under fed condition.CTRI/2020/03/024404Shilpa Medicare Limited35
已完成
不适用
Open label multicenter randomized parallel single-period single dose bio equivalence study of Leuprolide acetate 30 mg in adult male subjects with advanced prostaticcancer undergoing initial therapy.CTRI/2020/10/028442Pharmathen SA32
已完成
不适用
To evaluate bioavailability of oral Capecitabine in adult human cancer patients under fed conditionsCTRI/2021/06/034321ShilpaMedicareLimited35
已完成
不适用
Bioequivalence study of Capecitabine Tablets USP, 500 mg in adult human cancer patients under fed conditions.CTRI/2022/07/044491ovugen Oncology Sdn Bhd40